ASH Clinical News ACN_6.6s_SUPP_web | Page 3

OS in treatment-naïve BPDCN patients treated with ELZONRIS (n=29, 12 mcg/kg) 9
1.0
0.9
0.8
0.7
MEDIAN OS
NOT YET REACHED
0.6
0.5
• Median follow-up
25 months 9
0.4
0.3
Long-term survivors
continue to be observed
0.2
0.1
0.0
0
6
12
18
24
30
36
42
48
Months
OS = overall survival.
Reprinted with permission from Massachusetts Medical Society.
Before ELZONRIS, there was no standard of care for BPDCN 4
According to the NCCN Guidelines, when patients are treated with chemotherapy, BPDCN prognosis
is poor and median OS is approximately 8 to 12 months. 1
Visit ELZONRIS.COM/HCP to learn more
Hepatotoxicity
• Elevations in liver enzymes can occur with ELZONRIS. Grade 3
or higher elevations in liver enzymes occurred in approximately
40% of patients in clinical trials
• Monitor alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) prior to each infusion with ELZONRIS.
Temporarily withhold ELZONRIS if the transaminases rise to
greater than 5 times the upper limit of normal (ULN) and resume
treatment upon normalization or when resolved
ADVERSE REACTIONS:
The most common adverse reactions in the clinical trials
(incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue,
peripheral edema, pyrexia, and weight increase. The most common
laboratory abnormalities (incidence ≥ 50%) are decreases in
albumin, platelets, hemoglobin, calcium, sodium, and increases in
glucose, ALT, and AST.
To report SUSPECTED ADVERSE REACTIONS, contact Stemline
Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines ® ) for Acute Myeloid Leukemia V.3.2020. © National Comprehensive
Cancer Network, Inc. 2019. All rights reserved. Accessed December 23, 2019. To view the most
recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of
any kind whatsoever regarding their content, use or application and disclaims any responsibility for
their application or use in any way. 2. ELZONRIS [prescribing information]. New York, NY, US: Stemline
Therapeutics, Inc.; December 2018. 3. Data on file. Stemline Therapeutics, Inc. 4. Pagano L, Valentini
CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and
therapeutical approaches. Br J Haematol. 2016;174(2):188-202. 5. Laribi K, Denizon N, Besançon A,
et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. Biol
Blood Marrow Transplant. 2016;22(8):1357-1367. 6. Facchetti F, Cigognetti M, Fisogni S, Rossi G,
Lonardi S, Vermi W. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016;29(2):98-
111. 7. Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to
interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood.
2014;124(3):385-392. 8. Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell
neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239-
246. 9. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell
neoplasm. N Engl J Med. 2019;380(17):1628-1637.
ELZONRIS ® is a registered trademark of Stemline Therapeutics, Inc.
Copyright 2020 - Stemline Therapeutics, Inc. All rights reserved. 3/2020 US-ELZ-00291